Javier Loscertales
YOU?
Author Swipe
View article: Observational retrospective study of the treatment of Waldenström’s macroglobulinemia with ibrutinib in routine clinical practice in Spain
Observational retrospective study of the treatment of Waldenström’s macroglobulinemia with ibrutinib in routine clinical practice in Spain Open
Background: Waldenström’s macroglobulinemia (WM) is a B-cell neoplasia characterized by the infiltration of lymphoplasmacytic lymphoma cells in the bone marrow and abnormal secretion of IgM paraprotein. Ibrutinib, a Bruton tyrosine kinase …
View article: 215 | DISCONTINUATION OF BTK INHIBITOR MONOTHERAPY IN CLL PATIENTS WITHOUT DISEASE PROGRESSION: A REAL‐WORLD STUDY FROM THE SPANISH CLL GROUP (GELLC)
215 | DISCONTINUATION OF BTK INHIBITOR MONOTHERAPY IN CLL PATIENTS WITHOUT DISEASE PROGRESSION: A REAL‐WORLD STUDY FROM THE SPANISH CLL GROUP (GELLC) Open
View article: T-cell prolymphocytic leukemia, a case report and review of the literature
T-cell prolymphocytic leukemia, a case report and review of the literature Open
T-prolymphocytic leukemia is a rare and aggressive hematological malignancy characterized by the clonal proliferation of mature lymphoid T-cells. The pathogenesis of T-PLL is closely linked to specific chromosomal abnormalities, primarily …
View article: Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study Open
The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) fro…
View article: Evaluation of the novel therapeutic anti‐CCR7 antibody CAP‐100 as an add‐on therapy in chronic lymphocytic leukemia patients receiving venetoclax
Evaluation of the novel therapeutic anti‐CCR7 antibody CAP‐100 as an add‐on therapy in chronic lymphocytic leukemia patients receiving venetoclax Open
The Bruton's tyrosine kinase inhibitor ibrutinib and the B‐cell lymphoma 2 anti‐apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). However, there is a growing number of patients that r…
View article: Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients
Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients Open
Bruton’s tyrosine kinase inhibitor ibrutinib has significantly changed treatment landscape in chronic lymphocytic leukemia (CLL). Growing evidence supports ibrutinib to work beyond the effect on tumor cells by means of, for example, restor…
View article: Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study) Open
This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a l…
View article: Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody Open
View article: IMPACT OF DISEASE TREATMENT ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COVID‐19: A MULTICENTER STUDY ON BEHALF OF GELLC
IMPACT OF DISEASE TREATMENT ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH COVID‐19: A MULTICENTER STUDY ON BEHALF OF GELLC Open
Introduction: Patients (pts) with CLL are at risk of more severe COVID-19 clinical forms and worse survival compared to general population. Besides age and comorbidities, CLL treatments can aggravate an immune status otherwise impaired by …
View article: Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia, a novel therapeutic anti-CCR7 antibody.
Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia, a novel therapeutic anti-CCR7 antibody. Open
View article: Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL
Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL Open
Lymph node (LN) is a key tissue in the pathophysiology of mature blood cancers, especially for chronic lymphocytic leukemia (CLL). Within the multiple de-regulated pathways affecting CLL homeostasis, the CC-chemokine receptor 7 (CCR7) gran…
View article: S897 VALIDATION OF A NOVEL MECHANISM OF ACTION FOR TREATMENT OF CCR7+ HEMATOLOGICAL MALIGNANCIES WITH FIRST‐IN‐CLASS ANTIBODY CAP‐100
S897 VALIDATION OF A NOVEL MECHANISM OF ACTION FOR TREATMENT OF CCR7+ HEMATOLOGICAL MALIGNANCIES WITH FIRST‐IN‐CLASS ANTIBODY CAP‐100 Open
Background: The homeostatic CC‐chemokine receptor 7 (CCR7) controls trafficking of immune cells to the lymph node (LN). Accordingly, CCR7 is highly expressed in hematological malignancies with nodal involvement including chronic lymphocyti…
View article: IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL
IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL Open
Introduction: In the phase 3 HELIOS trial, coadministration of ibrutinib with bendamustine + rituximab (I + BR) improved patient outcomes compared with placebo + BR (Pbo + BR) in patients with previously treated chronic lymphocytic leukemi…
View article: IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY Open
View article: Treatment Of Essential Thrombocythemia In Europe : Observational Study Of 3649 Patients Of High Risk (Exels)
Treatment Of Essential Thrombocythemia In Europe : Observational Study Of 3649 Patients Of High Risk (Exels) Open
Treatment Of Essential Thrombocythemia In Europe : Observational Study Of 3649 Patients Of High Risk (Exels)
View article: Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2
Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2 Open
1Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; 2Department of Cancer Prevention, Faculty of Public Heath, Medical University of Silesia, Katowice, Poland; 3Department of Hematology, In…
View article: RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Open